RANI · Rani Therapeutics Holdings Inc
United States · RS rating 12 · As of 2026-11-03
| Price | 0.56 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 14 / 22 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 6 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +41.7% |
| Sales growth Q/Q | +16.9% |
| Distance from 52-week high | +77.8% |
| Market cap (USD) | $114.4M |